The Antidepressant Debate Is Asking the Wrong Question

For decades, psychiatry has focused much of its attention on the medication: Which antidepressant? What dose? How long? How quickly should we taper?

But after more than four decades of treating patients, I believe the most important variable has been sitting in front of us all along: the patient.

Two people can have the same diagnosis, take the same antidepressant at the same dose, and experience profoundly different results.

One responds beautifully. Another doesn’t. One experiences significant side effects. Another experiences none. One can eventually discontinue the medication with relatively little difficulty. Another can follow a careful taper and experience months of debilitating withdrawal.

Why? The medication may be identical. The biology is not.

Every patient comes to treatment with a different biological terrain: different genetics, nutritional status, metabolism, inflammatory burden, gastrointestinal health, hormonal influences, environmental exposures, and capacity to manufacture and regulate the neurotransmitters these medications affect.

Yet much of modern psychiatric treatment still begins with the diagnosis and the drug rather than with the biology of the individual.

I believe we have that equation backwards. The future of mental healthcare will not be found simply in prescribing more antidepressants—or fewer antidepressants. It will come from understanding the entire patient before we decide what the patient needs.

That principle matters when we prescribe medication. It matters while someone is taking medication. And it matters when we help someone stop taking it.

The national conversation about antidepressants has created an important opportunity to reconsider how these medications are prescribed and deprescribed. But if the debate becomes simply antidepressants are good versus antidepressants are bad, we will have missed the most important lesson.

The drug is only one part of the equation. The person taking it is the other. And that person may be the variable we have underestimated for far too long.

Antidepressants Don’t Manufacture Serotonin

One of the biggest misconceptions about antidepressants is that they “give” the brain serotonin. They don’t.

Selective serotonin reuptake inhibitors, or SSRIs, don’t manufacture serotonin. Instead, they block the serotonin transporter, allowing serotonin that has already been released into the synapse—the tiny space between nerve cells—to remain there longer. In effect, they make better use of the serotonin your brain is already producing.

That distinction is more than a matter of scientific accuracy. It changes the way we think about antidepressants—and about deprescribing.

Before serotonin can be released, recycled, or enhanced by an antidepressant, the brain has to make it in the first place. And producing serotonin is far more complicated than many people realize.

The process begins with tryptophan, an amino acid obtained from food. From there, the brain relies on a remarkable chain of biochemical reactions involving iron, vitamin B6, vitamin D, tetrahydrobiopterin, oxygen, and other nutrients and metabolic cofactors. Folate, vitamin B12, riboflavin, magnesium, zinc, inflammation, oxidative stress, hormones, intestinal health, and inherited genetic differences can also influence how efficiently this system functions.

These aren’t fringe ideas or “alternative medicine.” They’re basic human biochemistry. Yet before an antidepressant is prescribed, these factors are rarely evaluated. And before someone begins tapering off that medication, they’re almost never considered.

Imagine asking a construction crew to rebuild a house after removing the scaffolding—but neglecting to provide lumber, nails, or concrete. No one would expect the project to go well.

The brain faces a similar challenge during antidepressant deprescribing.

As long as the medication is present, it can help compensate for weaknesses in serotonin signaling. But when that pharmacological support is gradually withdrawn, the brain must once again rely on its own ability to manufacture, regulate, and maintain healthy serotonin activity.

If important biological building blocks are missing, that transition may be far more difficult than expected. That’s why I’ve come to believe we’re asking the wrong question about deprescribing. Instead of focusing exclusively on how to taper the medication, we should also be asking:

Does this patient’s brain and body have what they need to adapt as the medication is reduced or removed?

Deprescribing Doesn’t Happen in a Vacuum

Why do two people taking the same antidepressant have such different experiences when they stop?

Because withdrawal isn’t caused by the medication alone. It’s the result of an interaction between the medication and the biology of the person taking it.

Over time, the brain adapts to the continued presence of an SSRI. Receptors become less sensitive. Transporters adjust. Signaling pathways recalibrate. This isn’t addiction. It’s the brain doing what it always does: adapting to a changing environment.

When the medication is gradually reduced, the brain has to adapt once again.

For one person, that transition may be relatively smooth. Another may enter the same taper with nutritional deficiencies, impaired absorption, chronic inflammation, metabolic differences, or other biological vulnerabilities that affect the brain’s ability to adapt.

In some cases, the antidepressant may have been compensating for an already fragile serotonin system. When the medication is withdrawn, those underlying vulnerabilities haven’t necessarily disappeared—but the pharmacological support gradually does.

Seen through that lens, one of the most puzzling aspects of antidepressant deprescribing becomes easier to understand.

Why does one person experience only mild symptoms while another struggles for months?

The answer may not lie in the medication alone. It may lie in the biology of the person taking it.

That also helps explain why tapering slowly—while absolutely essential—isn’t always enough. Reducing the dose more gradually decreases the speed of physiological change. That’s important. But slowing the taper doesn’t automatically address biological vulnerabilities that may affect the brain’s ability to adapt.

Tapering addresses the medication. We also need to understand the patient.

Vitamin D Illustrates the Missing Piece

Vitamin D offers one example of this biological reality.

Vitamin D deficiency is remarkably common among people with depression. Yet vitamin D doesn’t just affect bone health or the immune system. It also plays an important role in regulating tryptophan hydroxylase 2, the key enzyme the brain uses to manufacture serotonin.

Imagine a patient whose vitamin D levels are already low before starting an antidepressant.

The medication may improve serotonin signaling enough to relieve symptoms. But it hasn’t necessarily corrected the underlying deficiency. The brain may still be operating with a reduced capacity to manufacture serotonin on its own.

Now imagine that same patient begins tapering off the medication: The brain must adapt to the loss of pharmacological support while the original biological vulnerability remains.

That doesn’t mean vitamin D deficiency is the cause of antidepressant withdrawal. And correcting a deficiency is no guarantee that withdrawal will be easy. Withdrawal is far too complex for any single nutrient to explain. But it illustrates a much larger principle:

If a correctable biological weakness affects the very pathway an antidepressant has been supporting, why wouldn’t we want to identify and address it before asking the brain to function without that medication?

And vitamin D is only an example.

Iron, vitamin B6, folate, vitamin B12, riboflavin, magnesium, zinc, tryptophan availability, thyroid function, inflammation, intestinal absorption, genetics, and other factors can influence the systems involved in mood and neurotransmitter function.

But the specific vulnerability won’t be the same for every patient.

That’s exactly the point. There is no universal biology. Every patient brings different nutritional reserves, genetics, inflammatory burdens, metabolic strengths and vulnerabilities to treatment.

The goal isn’t to find the cause of withdrawal. It’s to understand this patient—and address as many modifiable vulnerabilities as possible before, during, and after a carefully planned taper.

What Four Decades of Clinical Practice Have Taught Me

I wrote Functional Medicine for Antidepressant Withdrawal because I believe we’ve been asking the wrong questions.

Most deprescribing protocols understandably focus on the medication: Which antidepressant is the patient taking? What is the dose? What is its half-life? How slowly should it be tapered?

Those are important questions. In many cases, hyperbolic tapering and extremely small dose reductions—especially during the final stages of deprescribing—can make an enormous difference. But they aren’t the only questions that matter.

The patient is not simply a container from which a drug is being removed. The patient is a living biological system that must adapt as that medication is gradually withdrawn.

After more than four decades of treating patients, I’ve learned that the most important question is often not simply, “How much?” or “What dose?”

It is: “Who is this patient?”

What is happening biologically in this individual? What might make this person more resilient—or more vulnerable—as the medication is withdrawn? And what can we identify and address before asking their brain to make that transition?

In my clinical practice, I’ve repeatedly seen patients benefit when we assess nutritional status, support the biochemical pathways involved in neurotransmitter production, address inflammation where appropriate, and consider the individual’s genetic and metabolic profile before and during tapering.

Does that mean every withdrawal syndrome can be prevented? Of course not.

Antidepressant withdrawal is too complex—and human biology too individual—for anyone to make that promise. But it has convinced me that we should stop viewing withdrawal as simply a pharmacological problem.

We need to understand the biology of the individual experiencing it.

That’s also where I believe the next generation of research needs to go: beyond the medication alone and toward identifying the biological factors that might help us predict who is likely to struggle and how we might better support them.

The extraordinary differences we see from one patient to the next aren’t scientific noise. They’re the clue.

Better Prescribing Begins with Better Questions

Antidepressants should never be reduced to a debate about whether they are “good” or “bad.”

Some people are prescribed antidepressants when other interventions might have addressed factors contributing to their depression. Some experience devastating withdrawal because tapering was poorly planned or important biological vulnerabilities were never identified. Others remain profoundly depressed and suffer because they never receive adequate treatment at all.

And many patients benefit enormously from antidepressants, sometimes for years. They should never be made to feel ashamed of taking a medication that has restored their health and their lives.

That’s why I believe we’ve been asking the wrong question.

The question isn’t: Are antidepressants good or bad?

The better question is: What does this particular patient need?

Before prescribing medication, we should look beyond symptoms to understand the biological, psychological, and social factors contributing to depression. During treatment, we should continually ask whether the medication remains helpful and necessary. And before deprescribing, we should consider the biological factors that may influence how successfully this particular patient adapts as the medication is withdrawn.

This isn’t about being pro-medication or anti-medication. It’s about practicing personalized medicine.

The Patient Is the Most Important Variable

The debate over antidepressants will continue. We will debate how often they should be prescribed, how long patients should remain on them, and the safest ways to discontinue them. Those are important conversations.

But when it comes to antidepressant withdrawal, I believe we are still overlooking the most important question:

Why can two people taking the same medication, at the same dose, have profoundly different experiences when they stop?

The answer cannot be found by studying the medication alone. We need to study the person taking it.

That doesn’t diminish the importance of careful, gradual tapering. It expands our understanding of what safe deprescribing requires. We need to ask not only how quickly should we reduce this medication? But, who is the person whose brain and body must adapt as we reduce it?

What biological vulnerabilities might make that transition more difficult? What can we identify before tapering begins? What can we address? And how can we build a deprescribing plan around the individual rather than expecting the individual to conform to a standardized plan?

This is personalized medicine applied to antidepressant withdrawal.

The extraordinary differences we see from one patient to the next aren’t scientific noise. They’re the clue.

They are telling us that the future of safer antidepressant deprescribing won’t come from finding one perfect tapering schedule for everyone. It will come from combining thoughtful tapering with a much deeper understanding of the individual patient.

For too long, we’ve studied the medication while overlooking the individual. It’s time to reverse that equation.

Because the most important variable in antidepressant treatment—and antidepressant deprescribing—has never been the drug alone.

It’s the person taking it.